Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms

In this case report, we describe a case of sequential acquired CCDC6-RET fusion and BRAF V600E mutation observed in a patient with EGFR-mutated NSCLC treated with osimertinib and with combined selpercatinib and osimertinib. The discovery of genomic resistance mechanisms was facilitated by serial liq...

Full description

Saved in:
Bibliographic Details
Main Authors: Arianna Marinello, MD, Claudia Parisi, MD, Damien Vasseur, PhD, David Combarel, PharmD, Juliette Bihoreau, NP, Pernelle Lavaud, MD, Rémy Ezzedine, MD, Lodovica Zullo, MD, Luc Friboulet, PhD, Gerard Zalcman, MD, PhD, Antoine Italiano, MD, PhD, Benjamin Besse, MD, PhD, Mihaela Aldea, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR-mutated NSCLC
RET fusion
BRAF V600E
Selpercatinib
Trametinib
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001437
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324001437

Similar Items